Previous studies have demonstrated the inhibitory effects of compounds such as Alsterpaullone [35], Fostamatinib [36], Olomoucine [37], and Seliciclib [38] on CDK1 activity, while agents like Adavosertib [39] and Fostamatinib [40] target WEE1, thereby indirectly modulating CDK1 activity and inhibiting cancer progression. The gene discussed is CDK1; the disease is cancer.